{"id":6376,"date":"2024-12-24T15:50:04","date_gmt":"2024-12-24T10:20:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6376"},"modified":"2024-12-24T16:32:20","modified_gmt":"2024-12-24T11:02:20","slug":"parkinsons-disease-therapy-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market","title":{"rendered":"Parkinson\u2019s Disease: Impact of Emerging Therapies on the Therapeutics Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1efd0ae67c2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1efd0ae67c2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Parkinsons_Disease_Market_Dynamics\" >Parkinson\u2019s Disease Market Dynamics<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Drivers_Increasing_Prevalence_of_Parkinsons_Disease\" >Drivers: Increasing Prevalence of Parkinson\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Restraints_Availability_of_Alternative_Treatments\" >Restraints: Availability of Alternative Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Opportunities_Patent_Expirations_of_Existing_Drugs\" >Opportunities: Patent Expirations of Existing Drugs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Parkinsons_Disease_Epidem_Segmentation\" >Parkinson\u2019s Disease Epidem Segmentation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Parkinsons_Disease_Competitive_Landscape\" >Parkinson&#8217;s Disease Competitive Landscape<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Key_Players_in_the_Parkinsons_Disease_Market\" >Key Players in the Parkinson&#8217;s Disease Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Parkinsons_Disease_Market_Share_Analysis\" >Parkinson&#8217;s Disease Market Share Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Whats_New_in_Parkinsons_Treatment\" >What&#8217;s New in Parkinson&#8217;s Treatment?&nbsp;<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\/#Future_Outlook\" >Future Outlook<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Parkinson\u2019s disease<\/strong> is a complex neurodegenerative disorder that affects millions worldwide, with increasing prevalence as populations age. The market for Parkinson\u2019s disease treatments is expanding rapidly, driven by rising awareness of <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><strong><em>what Parkinson\u2019s disease is<\/em><\/strong><\/a>, advancements in research, and improvements in healthcare systems.<strong> In 2023, the United States Parkinson\u2019s disease market size was USD 1.8 billion.<\/strong> This growth underscores the rising demand for therapies targeting both the symptoms and progression of the condition. Despite established treatments, significant unmet needs remain, particularly for therapies that address the underlying causes and improve life expectancy for Parkinson&#8217;s patients across all stages of Parkinson&#8217;s disease.<\/p>\n\n\n\n<p>Emerging <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights\">Parkinson\u2019s disease therapies<\/a> are reshaping the landscape, offering hope for more effective management of the condition and slowing its progression. These advancements aim to address critical aspects of Parkinson\u2019s disease progression, including alpha-synuclein aggregation and mitochondrial dysfunction. The introduction of novel treatments, such as gene therapies and advanced drug delivery systems, aligns with the growing interest in understanding Parkinson\u2019s disease and how to combat it. As the global population faces an increase in <em>Parkinson&#8217;s disease cases<\/em>, particularly in later stages, these innovations provide new opportunities to manage symptoms and improve quality of life. The evolving therapeutic pipeline reflects a significant shift in the approach to treating Parkinson\u2019s disease, promising better outcomes for patients navigating the various stages of Parkinson&#8217;s disease progression.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-market-dynamics\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Market_Dynamics\"><\/span>Parkinson\u2019s Disease Market Dynamics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Parkinson\u2019s disease market is shaped by a combination of drivers, restraints, and opportunities that influence its growth and future trajectory.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-drivers-increasing-prevalence-of-parkinson-s-disease\"><span class=\"ez-toc-section\" id=\"Drivers_Increasing_Prevalence_of_Parkinsons_Disease\"><\/span>Drivers: Increasing Prevalence of Parkinson\u2019s Disease<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Parkinson\u2019s disease is becoming more prevalent globally due to aging populations and environmental risk factors. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-epidemiology-forecast\"><strong>increasing prevalence of Parkinson\u2019s disease<\/strong><\/a> highlights the urgency to address this growing health challenge. The disease manifests with hallmark motor symptoms such as bradykinesia, rigidity, tremors, and postural instability, alongside non-motor symptoms like cognitive impairment and depression, which significantly reduce the quality of life. As the burden of Parkinson\u2019s disease continues to rise, there is growing demand for effective treatments that address both motor and non-motor aspects of the condition.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-restraints-availability-of-alternative-treatments\"><span class=\"ez-toc-section\" id=\"Restraints_Availability_of_Alternative_Treatments\"><\/span>Restraints: Availability of Alternative Treatments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Despite advancements in Parkinson\u2019s therapies, the availability of alternative treatments poses a challenge to the market. Established pharmacological treatments like carbidopa\/levodopa and formulations such as DUOPA and RYTARY offer reliable symptom management. Additionally, non-pharmacological interventions and surgical options like deep brain stimulation provide viable alternatives for many patients. These existing therapies, combined with their widespread use and familiarity among clinicians, can slow the adoption of newer treatments entering the market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-opportunities-patent-expirations-of-existing-drugs\"><span class=\"ez-toc-section\" id=\"Opportunities_Patent_Expirations_of_Existing_Drugs\"><\/span>Opportunities: Patent Expirations of Existing Drugs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The impending patent expirations of several established Parkinson\u2019s disease drugs create significant opportunities for the market. Generic versions of key therapies will not only make treatments more accessible but also open avenues for the development of novel drugs and improved formulations. Additionally, the robust pipeline of emerging therapies, including a-synuclein-targeting drugs, gene therapies, and regenerative approaches, promises to redefine the therapeutic landscape. Late-stage candidates such as SPN-830, tavapadon, P2B001, and ND0612 hold the potential to address critical unmet needs, particularly in motor symptom control and disease modification, marking a new era of innovation in Parkinson\u2019s disease treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-epidem-segmentation\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Epidem_Segmentation\"><\/span>Parkinson\u2019s Disease Epidem Segmentation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Parkinson\u2019s disease market is segmented to provide a detailed understanding of the patient population and treatment needs across the <strong>7MM (United States, EU4 countries, United Kingdom, and Japan) <\/strong>from<strong> 2020 to 2034.<\/strong><\/p>\n\n\n\n<p>Key categories include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Diagnosed Prevalent Cases<\/strong><\/li>\n\n\n\n<li><strong>Gender-Specific Cases<\/strong><\/li>\n\n\n\n<li><strong>Age-Specific Cases<\/strong><\/li>\n\n\n\n<li><strong>Stage-Specific Cases<\/strong><\/li>\n\n\n\n<li><strong>Psychosis Due to Parkinson&#8217;s Disease<\/strong><\/li>\n\n\n\n<li><strong>MCI Due to Parkinson&#8217;s Disease<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"372\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-1024x372.png\" alt=\"Parkinson\u2019s-Disease-Epidem-Insights-(2023)\" class=\"wp-image-30672\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-1024x372.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-300x109.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-150x55.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-768x279.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-1536x559.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/24151721\/Parkinsons-Disease-Epidem-Insights-2023-2048x745.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>This segmentation ensures a comprehensive view of the market, supporting tailored therapeutic strategies and forecasting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-competitive-landscape\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Competitive_Landscape\"><\/span>Parkinson&#8217;s Disease Competitive Landscape<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><strong>Parkinson&#8217;s disease market<\/strong><\/a> is fiercely competitive, driven by the continuous pursuit of innovative solutions to address the unmet needs of patients. Established pharmaceutical companies, emerging biotechs, and research-driven organizations are actively contributing to the evolution of <strong>Parkinson&#8217;s disease therapies<\/strong>. The market is witnessing a surge in demand, fueled by advancements in treatment options, diagnostic techniques, and ongoing research.<\/p>\n\n\n\n<p>New entrants, such as Sunovion and Accorda, are making strides in developing rescue medications aiming to cater to acute symptom management. Simultaneously, several companies are advancing pipeline drugs that target underlying pathologies and motor symptoms, seeking to fill gaps in the <strong>Parkinson&#8217;s disease therapeutic market<\/strong>. Emerging therapies, combined with state-of-the-art diagnostic tools, are set to transform the <strong>Parkinson&#8217;s disease therapeutic area<\/strong>, driving growth in the market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-players-in-the-parkinson-s-disease-market\"><span class=\"ez-toc-section\" id=\"Key_Players_in_the_Parkinsons_Disease_Market\"><\/span>Key Players in the Parkinson&#8217;s Disease Market<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Major players dominating the <strong>Parkinson&#8217;s disease therapeutic market<\/strong> include GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, and AbbVie Inc. Companies like ACADIA Pharmaceuticals Inc., Novartis, Lundbeck, and UCB Biopharma SRL are also contributing significantly to the <strong>Parkinson&#8217;s disease market size<\/strong> through innovative products and therapies. Emerging players such as Annovis Bio, Pharma Two B, Supernus Pharmaceuticals, Mitsubishi Tanabe Pharma (NeuroDerm), and Cerevel Therapeutics, LLC are expected to influence the competitive landscape with novel therapeutic approaches.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-market-share-analysis\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Market_Share_Analysis\"><\/span>Parkinson&#8217;s Disease Market Share Analysis<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to DelveInsight\u2019s analysis, the <strong>Parkinson&#8217;s disease therapeutic market<\/strong> in 2023 was dominated by combination therapies and established medications, generating<strong> approximately USD 2 million<\/strong> in revenue. This significant market share reflects the reliance on proven pharmacological treatments, with an increasing focus on diversifying options through emerging therapies and personalized care solutions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-s-new-in-parkinson-s-treatment-nbsp\"><span class=\"ez-toc-section\" id=\"Whats_New_in_Parkinsons_Treatment\"><\/span>What&#8217;s New in Parkinson&#8217;s Treatment?&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <strong>Parkinson&#8217;s disease market<\/strong> has seen remarkable advancements in recent months. On <strong>November 1, 2024, <\/strong>Sunbird Bio announced groundbreaking diagnostic technology capable of classifying Parkinson&#8217;s-positive patients with 86% accuracy by detecting aggregated alpha-synuclein proteins. This innovation represents a major leap in early diagnosis, enabling timely and effective interventions.<\/p>\n\n\n\n<p>Further expanding the <strong>Parkinson&#8217;s disease therapeutic area<\/strong>, Cerevance initiated its Phase 3 ARISE trial on November 18, 2024, dosing the first patient with solengepras, a novel adjunctive therapy designed for tailored intervention. This approach underscores the shift toward precision medicine in <strong>Parkinson&#8217;s disease therapies<\/strong>.<\/p>\n\n\n\n<p>In <strong>December 2024<\/strong>, AbbVie revealed positive topline results from its pivotal Phase III TEMPO-2 trial evaluating tavapadon, a first-in-class D1\/D5 partial agonist. As a flexible-dose monotherapy for early-stage Parkinson\u2019s, tavapadon achieved both primary and secondary endpoints, promising to redefine the dopamine agonist market and further augment the <strong>Parkinson&#8217;s disease market size<\/strong>.<\/p>\n\n\n\n<p>These advancements signify a rapidly evolving <strong>Parkinson&#8217;s disease therapeutic market<\/strong>, with ongoing innovations poised to reshape the treatment landscape and improve patient outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook\"><span class=\"ez-toc-section\" id=\"Future_Outlook\"><\/span>Future Outlook<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future of the <strong>Parkinson&#8217;s disease therapeutic market<\/strong> holds immense promise as research and innovation continue to push the boundaries of treatment possibilities. Pharmaceutical companies are shifting their focus toward developing therapies that not only manage symptoms but also target the disease&#8217;s underlying pathology. Advances in understanding mechanisms such as alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation are paving the way for disease-modifying treatments that could significantly slow or halt the progression of Parkinson&#8217;s disease.<\/p>\n\n\n\n<p>Emerging technologies, including brain-penetrant drugs, gene therapies, and advanced delivery systems, offer the potential for greater efficacy and precision in managing the disease. Biomarker-driven approaches are set to revolutionize early detection and patient stratification, enabling tailored interventions that improve outcomes. With ongoing research into genetic factors and neuroprotective agents like GLP-1 agonists, new therapeutic strategies are poised to emerge, further enhancing care. Combined with a growing emphasis on holistic management, including dietary and lifestyle considerations, the future of Parkinson&#8217;s disease treatment promises a brighter outlook for patients navigating this challenging condition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-30639\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson\u2019s disease is a complex neurodegenerative disorder that affects millions worldwide, with increasing prevalence as populations age. The market for Parkinson\u2019s disease treatments is expanding rapidly, driven by rising awareness of what Parkinson\u2019s disease is, advancements in research, and improvements in healthcare systems. In 2023, the United States Parkinson\u2019s disease market size was USD 1.8 [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30692,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[6833,6831],"industry":[17225],"therapeutic_areas":[17229],"class_list":["post-6376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-parkinsons-disease-market","tag-parkinsons-disease-therapy-market","industry-pharmaceutical","therapeutic_areas-central-nervous-system"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Impact of Emerging therapies on Parkinson\u2019s therapeutics market<\/title>\n<meta name=\"description\" content=\"Parkison&#039;s disease novel pipeline and expanded pharmacological knowledge will influence Parkinson\u2019s disease therapy market dramatically...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impact of Emerging therapies on Parkinson\u2019s therapeutics market\" \/>\n<meta property=\"og:description\" content=\"Parkison&#039;s disease novel pipeline and expanded pharmacological knowledge will influence Parkinson\u2019s disease therapy market dramatically...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-24T10:20:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T11:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/24154753\/Parkinsons-disease-Therapy-Market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Impact of Emerging therapies on Parkinson\u2019s therapeutics market","description":"Parkison's disease novel pipeline and expanded pharmacological knowledge will influence Parkinson\u2019s disease therapy market dramatically...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market","og_locale":"en_US","og_type":"article","og_title":"Impact of Emerging therapies on Parkinson\u2019s therapeutics market","og_description":"Parkison's disease novel pipeline and expanded pharmacological knowledge will influence Parkinson\u2019s disease therapy market dramatically...","og_url":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-24T10:20:04+00:00","article_modified_time":"2024-12-24T11:02:20+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/24154753\/Parkinsons-disease-Therapy-Market.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market","url":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market","name":"Impact of Emerging therapies on Parkinson\u2019s therapeutics market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/24154753\/Parkinsons-disease-Therapy-Market.png","datePublished":"2024-12-24T10:20:04+00:00","dateModified":"2024-12-24T11:02:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Parkison's disease novel pipeline and expanded pharmacological knowledge will influence Parkinson\u2019s disease therapy market dramatically...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/24154753\/Parkinsons-disease-Therapy-Market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/24154753\/Parkinsons-disease-Therapy-Market.png","width":466,"height":284,"caption":"Impact of Emerging Therapies on the Therapeutics Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/24154753\/Parkinsons-disease-Therapy-Market-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapy market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease market<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapy market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 24, 2024","modified":"Updated on Dec 24, 2024"},"absolute_dates_time":{"created":"Posted on Dec 24, 2024 3:50 pm","modified":"Updated on Dec 24, 2024 4:32 pm"},"featured_img_caption":"Impact of Emerging Therapies on the Therapeutics Market\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6376"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6376\/revisions"}],"predecessor-version":[{"id":30698,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6376\/revisions\/30698"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30692"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6376"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6376"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}